1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
XOMA Corporation

XOMA Corporation

XOMAP
XOMA CorporationUS flagNASDAQ Global Market
25.51
USD
+0.05
- -
307.74MMarket Cap
XOMA Corporation
XOMAP
(NASDAQ Global Market)

Recent

price

25.51

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Tangible Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic Weighted Avg Shares
34
58
34
35
19
55
6
53
5
18
29
38
6
5
10
12
8
Sales/Revenue/Turnover
-199.23
-58.35
-152.6
-163.26
-433.31
-64.97
-1,024.3
38.87
-282.05
-21.15
42.25
45.94
-288.93
-493.13
-391.15
97.63
65.01
Operating Margin (%)
6
5
4
3
2
2
1
- -
- -
- -
- -
- -
- -
1
- -
3
3
Depreciation Expense
-69
-33
-71
-124
-38
-21
-54
15
-13
-2
13
16
-17
-41
-14
32
34
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
10.22
- -
- -
- -
0.57
- -
- -
- -
0.32
0.31
Effective Tax Rate (%)
-204.38
-56.26
-210.36
-349.94
-203.02
-37.16
-962.08
27.7
-251.8
-10.79
45.25
41.4
-283.79
-858.15
-135.23
271.97
441.79
Profit Margin (%)
23
42
72
97
47
49
-5
37
42
51
76
84
54
150
101
82
86
Working Capital
14
34
38
35
16
43
25
15
22
28
13
- -
- -
119
107
117
108
LT Debt
24
15
21
-4
3
-2
-47
6
19
44
86
142
124
89
62
84
113
Total Equity
- -
- -
- -
- -
- -
- -
- -
204.82
- -
- -
- -
13.95
- -
- -
- -
5.72
2.27
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
-1.36
- -
- -
- -
-1.4
- -
- -
- -
-4.05
-4.26
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
17
15
16
LT Borrowings
94
96
89
LT Finance Leases
21
20
20
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
12
12
12
Market Capitalization
- -
- -
- -

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
111
117
119
Cash, Cash Equivalents & STI
47
83
86
Accounts Receivable, Net
4
5
5
Inventories
- -
- -
- -
Total Current Liabilities
28
35
33
Payables & Accruals
7
9
7
ST Debt
17
15
16
Deferred Revenue
1
1
1

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
231.61%
5.7%
35.6%
Free Cash Flow
-94.43%
92.58%
29.68%
Net Income, GAAP
-146.14%
-89.27%
-329.45%
Sales/Revenue/Turnover
102.72%
10.7%
14.09%
Total Cash Common Dividend
- -
- -
-94.72%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1
6
1
2
10
2025
4
5
1
1
12
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Applied Therapeutics, Inc. (APLT)
La Jolla Pharmaceutical Company (LJPC)
Relay Therapeutics, Inc. (RLAY)
Traws Pharma, Inc. (TRAW)
Spexis AG (PPHOF)
Lakewood-Amedex Biotherapeutics Inc. Common Stock (LABT)
Business
XOMA Royalty Corporation (NASDAQ: XOMA), formerly XOMA Corporation, operates as a biotechnology royalty aggregator that acquires economic rights to future milestone and royalty payments from pre-commercial clinical candidates and commercial therapies licensed to pharmaceutical and biotechnology partners; its portfolio encompasses over 120 such assets spanning multiple therapeutic areas and development stages, including commercial products like VABYSMO (faricimab-svoa) for neovascular age-related macular degeneration and diabetic macular edema, OJEMDA (tovorafenib), MIPLYFFA (arimoclomol), XACIATO (clindamycin phosphate vaginal gel 2%), IXINITY (coagulation factor IX recombinant), and DSUVIA (sufentanil sublingual tablet), as well as early- to mid-stage investigational candidates such as those from partners including Roche, Day One Biopharmaceuticals, Zevra Therapeutics, Rezolute, Gossamer Bio, and Takeda; the company targets development-stage assets with blockbuster potential from well-capitalized partners and royalties on therapies addressing specific patient populations, employing a portfolio approach to mitigate single-asset risk while operating a capital-efficient structure where partners bear all R&D costs. Founded in 1981 and headquartered in Emeryville, California, XOMA Royalty conducts its activities primarily in the United States, Asia Pacific, Europe, and Switzerland, providing non-dilutive, non-recourse funding to sellers for advancing drug candidates or general corporate purposes. Recent developments include the completion of acquisitions for Turnstone Biologics at $0.34 per share plus a contingent value right and HilleVax at $1.95 per share plus a contingent value right; announcements of acquisitions for LAVA Therapeutics, securing interests in partnered assets PF-08046052 (Pfizer) and JNJ-89853413 (Johnson & Johnson), and Mural Oncology at $2.035 to $2.24 per share expected in Q4 2025; acting as structuring agent for XenoTherapeutics' acquisition of ESSA Pharma; a financing arrangement raising up to $140 million with Blue Owl Capital to support repurchases and further acquisitions; and portfolio advancements such as Zevra Therapeutics' MAA submission for arimoclomol in Niemann-Pick Type C, Rezolute's Phase 3 topline data expectations, and Gossamer Bio's Phase 3 trial progress.

Company News

APIChat

  • defenseworld.net

    XOMA (NASDAQ:XOMAP) Stock Price Down 1.5% – Time to Sell?